Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects

Frontiers in Immunology

Yongyin Li¹  Xiaotao Jiang²  Jiaxin Liang²  Xiaorui Hou²  Yixin Liu²  Zhuoyan Liu²  Xuan Liu⁴  Meichuan Zhang⁵ 

[1] D Department, Caleb BioMedical Technology Co. Ltd, Guangzhou, China;Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China;Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China;Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China;;R&

关键词: immunotherapy;    hepatocellular carcinoma;    HCC;    immune checkpoint inhibitors;    adoptive cell therapy;    vaccine;   

DOI  :  10.3389/fimmu.2021.765101

来源: DOAJ

【 摘 要 】

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional therapeutic options that will help only a limited percentage of HCC patients. Cancer immunotherapy has achieved dramatic advances in recent years and provides new opportunities to treat HCC. However, HCC has various etiologies and can evade the immune system through multiple mechanisms. With the rapid development of genetic engineering and synthetic biology, a variety of novel immunotherapies have been employed to treat advanced HCC, including immune checkpoint inhibitors, adoptive cell therapy, engineered cytokines, and therapeutic cancer vaccines. In this review, we summarize the current landscape and research progress of different immunotherapy strategies in the treatment of HCC. The challenges and opportunities of this research field are also discussed.

【 授权许可】

Unknown